Semantically I agree 1,000%. Because there's SO MUCH variability even within those trials themselves, who, how, when, etc.. But, THAT BEING SAID, even the variability evens out over time, because ALL THOSE STUDIES are (semantically & theorectically different). Which led me to my question:
Has there EVER been an AH drug that performed "better" as in the reported cognitive data SPECIFICALLY! Look mechanisms & how they are perceived, extrapolated, demonstrated & PRESENTED is important but leaves so much room for noise in a Phase 2 Trial. We have NO CONTROL for THAT specific study.
But the COGNITIVE DATA, how it impacts PERFORMANCE. Has ANY DRUG, again among the 138 or so Big Pharma has been trying to bring to market, EVER SHOWN this promise at this stage?
I think people dismiss the UNDERPINNINGS HERE: The underlying theory. Proteins FUNCTION relative to SHAPE/FORM & PERFORMANCE. The chemistry decides the shape & possibilities of the molecule: Designed or evolved to interact with those of similar (or in ways those UNLIKE) but the SHAPE is EVERYTHING. Misfolded proteins simply could be considered DYSFUNCTIONAL (denatured, even) & so RESTORING the STRUCTURE might RESTORE the FUNCTION. The studies I've read clearly show those misformed proteins tend to impact, contaminate, &/or otherwise cause problems (in other proteins they come into contact with) up & down stream. At least in mice we've seen this.
That simple differenct in theoretical approach is IMPORTANT I think & miles from what's been done in this area before. At least as best as I can tell. Now does it work. So far, we have data that says YES!
Now the NEXT STEP!
AI
Market Data 
Markets 
